Disease block
C81-C96 – Bösartige Neubildungen des lymphatischen, blutbildenden und verwandten Gewebes, als primär festgestellt oder vermutet
- Chapter II: Neubildungen
134Decisions
205Patient groups
Added benefit by patient group
- Major1
- Considerable21
- Minor22
- Non-quantifiable40
- Not proven121
Diseases in this disease block
- C81 Hodgkin-Lymphom [Lymphogranulomatose] 6 decisions
- C82 Follikuläres Lymphom 14 decisions
- C83 Nicht follikuläres Lymphom 23 decisions
- C84 Reifzellige T/NK-Zell-Lymphome 4 decisions
- C85 Sonstige und nicht näher bezeichnete Typen des Non-Hodgkin-Lymphoms 6 decisions
- C86 Weitere spezifizierte T/NK-Zell-Lymphome 2 decisions
- C88 Bösartige immunproliferative Krankheiten 5 decisions
- C90 Plasmozytom und bösartige Plasmazellen-Neubildungen 34 decisions
- C91 Lymphatische Leukämie 33 decisions
- C92 Myeloische Leukämie 16 decisions
- C93 Monozytenleukämie 10 decisions
- C94 Sonstige Leukämien näher bezeichneten Zelltyps 15 decisions
- C96 Sonstige und nicht näher bezeichnete bösartige Neubildungen des lymphatischen, blutbildenden und verwandten Gewebes 2 decisions
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2026-10-01BlenrepBelantamab-MafodotinNot proven: 2 of 2 patient groups
- 2026-10-01BlenrepBelantamab-MafodotinNon-quantifiable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2026-08-20TibsovoIvosidenibNot proven
- 2026-07-02MinjuviTafasitamabNon-quantifiable: 2 of 2 patient groups
- 2026-06-04BreyanziLisocabtagen maraleucelNot proven
- 2026-05-21ScemblixAsciminibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2026-04-16AyvakytAvapritinibNot proven
- 2026-04-16OmjjaraMomelotinibNot proven: 2 of 2 patient groups
- 2026-03-19LynozyficLinvoseltamabNot proven: 2 of 2 patient groups
- 2026-02-19DarzalexDaratumumabMinor
- 2026-02-19DarzalexDaratumumabMinor
- 2026-02-19SarclisaIsatuximabNot proven
- 2026-01-22OrdsponoOdronextamabNot proven
- 2026-01-22OrdsponoOdronextamabNot proven: 2 of 2 patient groups
- 2025-12-18CalquenceAcalabrutinibNot proven
- 2025-12-18CalquenceAcalabrutinibNot proven: 2 of 2 patient groups
- 2025-12-18CalquenceAcalabrutinibNot proven
- 2025-12-18CalquenceAcalabrutinibNot proven
- 2025-11-20ScemblixAsciminibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-11-06ColumviGlofitamabNot proven: 3 of 3 patient groups
- 2025-11-06ColumviGlofitamabNot proven: 2 of 2 patient groups
- 2025-10-02JaypircaPirtobrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2025-10-02BreyanziLisocabtagen maraleucelNot proven
- 2025-08-21BlincytoBlinatumomabConsiderable
- 2025-08-21InrebicFedratinibNon-quantifiable
- 2025-08-21BlincytoBlinatumomabNon-quantifiable
- 2025-08-21BlincytoBlinatumomabNon-quantifiable
- 2025-08-07SarclisaIsatuximabMinor
- 2025-08-07JaypircaPirtobrutinibNot proven
- 2025-05-15DarzalexDaratumumabNot proven
- 2025-05-15CarvyktiCiltacabtagen autoleucelConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-04-17TepkinlyEpcoritamabNot proven: 2 of 2 patient groups
- 2025-03-06TepkinlyEpcoritamabNot proven
- 2024-12-19YescartaAxicabtagen-CiloleucelMinor
- 2024-09-19AbecmaIdecabtagen vicleucelNot proven
- 2024-08-15InaqoviDecitabin/CedazuridinNot proven
- 2024-08-01VanflytaQuizartinibNot proven
- 2024-07-04ElrexfioElranatamabNot proven: 2 of 2 patient groups
- 2024-06-20PolivyPolatuzumab VedotinNot proven
- 2024-06-20PolivyPolatuzumab VedotinNot proven: 3 of 3 patient groups
- 2024-06-06BrukinsaZanubrutinibNot proven
- 2024-05-16DarzalexDaratumumabConsiderable
- 2024-05-02RydaptMidostaurinNot proven
- 2024-05-02RydaptMidostaurinNot proven
- 2024-04-04TepkinlyEpcoritamabNon-quantifiable
- 2024-03-07TalveyTalquetamabNon-quantifiable
- 2024-02-15TecvayliTeclistamabNot proven
- 2024-02-15KymriahTisagenlecleucelNon-quantifiable
- 2024-02-15KymriahTisagenlecleucelNon-quantifiable
- 2023-12-21YescartaAxicabtagen-CiloleucelNot proven
- 2023-11-16BreyanziLisocabtagen maraleucelConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-11-02Zynlonta Loncastuximab tesirinNot proven: 2 of 2 patient groups
- 2023-10-05EbvalloTabelecleucelNon-quantifiable
- 2023-07-20ImbruvicaIbrutinibNot proven: 2 of 2 patient groups
- 2023-06-15BrukinsaZanubrutinibMinor: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2023-06-15BrukinsaZanubrutinibNot proven
- 2023-06-15BrukinsaZanubrutinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-04-06BreyanziLisocabtagen maraleucelNot proven
- 2023-03-16TecartusBrexucabtagen autoleucelNon-quantifiable
- 2023-03-16PepaxtiMelphalanflufenamidNot proven
- 2023-03-16ScemblixAsciminibMinor
- 2023-03-16NexpovioSelinexorNot proven
- 2023-03-16NexpovioSelinexorNot proven
- 2022-12-15LunsumioMosunetuzumabNon-quantifiable
- 2022-12-01KymriahTisagenlecleucelNon-quantifiable
- 2022-11-03YescartaAxicabtagen-CiloleucelNon-quantifiable: 2 of 2 patient groups
- 2022-09-15DarzalexDaratumumabConsiderable
- 2022-07-21CopiktraDuvelisibNot proven
- 2022-07-21CopiktraDuvelisibNot proven: 4 of 4 patient groups
- 2022-06-16AbecmaIdecabtagen vicleucelNon-quantifiable
- 2022-06-16BrukinsaZanubrutinibNot proven
- 2022-04-21NinlaroIxazomibNon-quantifiable
- 2022-03-18DarzalexDaratumumabConsiderable
- 2022-03-03MinjuviTafasitamabNon-quantifiable
- 2022-02-03DarzalexDaratumumabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-01-20BlincytoBlinatumomabMajor
- 2021-12-16AdcetrisBrentuximab VedotinMinor
- 2021-12-16EmplicitiElotuzumabConsiderable
- 2021-12-02VenclyxtoVenetoclaxConsiderable
- 2021-12-02ElzonrisTagraxofuspNon-quantifiable
- 2021-11-19BosulifBosutinibNot proven
- 2021-11-04SarclisaIsatuximabNot proven
- 2021-11-04SarclisaIsatuximabMinor
- 2021-11-04GazyvaroObinutuzumabNot proven
- 2021-11-04GazyvaroObinutuzumabNot proven
- 2021-11-04GazyvaroObinutuzumabNot proven
- 2021-09-16KeytrudaPembrolizumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-09-02InrebicFedratinibNon-quantifiable
- 2021-08-05TecartusBrexucabtagen autoleucelNon-quantifiable
- 2021-08-05CalquenceAcalabrutinibConsiderable: 1 of 5 patient groupsMinor: 1 of 5 patient groupsNot proven: 3 of 5 patient groups
- 2021-07-15BlincytoBlinatumomabNon-quantifiable
- 2021-07-15KyprolisCarfilzomibNot proven
- 2021-06-03CalquenceAcalabrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-06-03CalquenceAcalabrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-04-01ImbruvicaIbrutinibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-02-18DaurismoGlasdegibConsiderable
- 2020-12-03PoteligeoMogamulizumabNon-quantifiable
- 2020-11-20IclusigPonatinibNon-quantifiable
- 2020-11-20IclusigPonatinibNon-quantifiable
- 2020-10-15VenclyxtoVenetoclaxNot proven: 3 of 3 patient groups
- 2020-08-20DarzalexDaratumumabNon-quantifiable
- 2020-08-20DarzalexDaratumumabMinor
- 2020-05-14XospataGilteritinibConsiderable
- 2020-02-20ImbruvicaIbrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2020-02-20ImbruvicaIbrutinibNot proven
- 2019-12-05Imnovid PomalidomidNot proven
- 2019-09-05AdcetrisBrentuximab VedotinNon-quantifiable
- 2019-08-15BlincytoBlinatumomabNon-quantifiable
- 2019-08-15BlincytoBlinatumomabNon-quantifiable
- 2019-05-16VenclyxtoVenetoclaxNot proven: 2 of 2 patient groups
- 2019-05-16VenclyxtoVenetoclaxMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-03-22Vyxeos liposomalDaunorubicin/CytarabinConsiderable
- 2019-02-21MylotargGemtuzumab OzogamicinNon-quantifiable
- 2019-02-21BosulifBosutinibNot proven: 2 of 2 patient groups
- 2018-07-05AdcetrisBrentuximab VedotinMinor
- 2018-02-15DarzalexDaratumumabNot proven
- 2018-02-15KyprolisCarfilzomibConsiderable: 2 of 2 patient groups
- 2018-01-18BesponsaInotuzumab ozogamicinMinor
- 2017-12-07BlincytoBlinatumomabConsiderable
- 2017-11-17KeytrudaPembrolizumabNot proven
- 2017-06-15OpdivoNivolumabNot proven
- 2017-03-16ImbruvicaIbrutinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-03-16ZydeligIdelalisibNon-quantifiable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2017-01-19AdcetrisBrentuximab VedotinNon-quantifiable
- 2016-12-15ImbruvicaIbrutinibNot proven: 3 of 3 patient groups
- 2016-12-01EmplicitiElotuzumabMinor
- 2016-09-15ZydeligIdelalisibNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-07-21ImbruvicaIbrutinibConsiderable: 1 of 6 patient groupsNon-quantifiable: 2 of 6 patient groupsNot proven: 3 of 6 patient groups
- 2016-03-17Imnovid PomalidomidConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-03-17FarydakPanobinostatNon-quantifiable
- 2015-03-19ZydeligIdelalisibNot proven
- 2013-05-16PixuvriPixantronNot proven
- 2013-05-16AdcetrisBrentuximab VedotinNon-quantifiable: 3 of 3 patient groups
- 2013-05-02DacogenDecitabinMinor
Data status: 2026-10-29